Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.

Inhaled aerosol viral-vectored vaccines against tuberculosis.

Stylianou E. and Satti I., (2024), Current opinion in virology, 66

Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial.

Wajja A. et al, (2023), The Lancet. Infectious diseases

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.

Wilkie M. et al, (2020), Vaccine, 38, 779 - 789

Cytomegalovirus infection is a risk factor for tuberculosis disease in infants.

Müller J. et al, (2019), JCI insight, 4

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.

Manjaly Thomas Z-R. et al, (2019), PLoS medicine, 16

Current approaches toward identifying a correlate of immune protection from tuberculosis

Satti I. and McShane H., (2019), Expert Review of Vaccines, 18, 43 - 59

Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection

O’Shea MK. et al, (2018), Scientific Reports, 8

Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A

Wajja A. et al, (2018)

Human Immunodeficiency Virus Infection Impairs Th1 and Th17 Mycobacterium tuberculosis–Specific T-Cell Responses

Murray LW. et al, (2018), The Journal of Infectious Diseases, 217, 1782 - 1792

Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines

Harris SA. et al, (2018), Tuberculosis, 108, 99 - 105

Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A.

Wajja A. et al, (2018), Wellcome open research, 3

Assay optimisation and technology transfer for multi-site immuno-monitoring in vaccine trials

Smith SG. et al, (2017), PLOS ONE, 12, e0184391 - e0184391

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial

Wajja A. et al, (2017), PLOS Neglected Tropical Diseases, 11, e0005440 - e0005440

TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development

Kaufmann SHE. et al, (2017), Frontiers in Immunology, 8

Correction: Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants

Fletcher HA. et al, (2016), Nature Communications, 7

T-cell activation is an immune correlate of risk in BCG vaccinated infants

Fletcher HA. et al, (2016), Nature Communications, 7

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults

Minhinnick A. et al, (2016), Vaccine, 34, 1412 - 1421

Optimization of a Human Bacille Calmette-Guérin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity

Minhinnick A. et al, (2016), Journal of Infectious Diseases, 213, 824 - 830

A Phase I Trial Evaluating Aerosol Administration Of A Candidate Tb Vaccine, Mva85a, As A Way To Induce Potent Local Cellular Immune Responses And Avoid Anti-Vector Immunity

Thomas Z-RM. et al, (2016), AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 193

S40 Optimisation of a human BCG challenge model

Wilkie MEM. et al, (2015), Thorax, 70, A27.1 - A27

Load More

Include forthcoming?